MedPath

This is a study to optimise the dosing regimen for Vancomycin so that patient response to the drug can be improved.

Not Applicable
Conditions
Health Condition 1: B958- Unspecified staphylococcus as thecause of diseases classified elsewhere
Registration Number
CTRI/2023/02/049473
Lead Sponsor
Prof Nusrat Shafiq
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Critically ill adults admitted to intensive care unit or emergency ward where intravenous vancomycin therapy is deemed necessary based on suspected or confirmed infectious aetiology.

Exclusion Criteria

Patients less than 18 years.

Patients requiring renal replacement therapy.

Patients with end stage renal disease.

Patients with end stage hepatic failure.

Any contraindication or history of hypersensitivity with use of vancomycin.

Pregnant and lactating women.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of patients achieving AUC 0-24 hours/MIC ratio more than 400 in both the treatment groups.Timepoint: Time points considered will be 15 minutes, 30 minutes, 2 hours, 6 hours, 23.5 hours after administration of dose.
Secondary Outcome Measures
NameTimeMethod
Duration of vasopressor support.Timepoint: 5 days of therapy.;Number of days from vancomycin initiation to intensive care unit discharge.Timepoint: 5 days of therapy.;Proportion of clinical failure at the end of treatment in both the treatment groups.Timepoint: 5 days of therapy.;Proportion of patients achieving trough concentration of 15-20 in both the treatment groups.Timepoint: Second day after starting therapy.;Proportion of patients alive at Day 28 in the treatment groups.Timepoint: At the end of 28 days.;Proportion of patients alive at the end of treatment in both the treatment groups.Timepoint: 5 days of therapy.;Proportion of patients requiring substitution of or addition to vancomycin with other antibiotics for the same indication.Timepoint: 5 days of therapy.;To compare the frequency of patient readmission between the treatment groups.Timepoint: At the end of 28 days.
© Copyright 2025. All Rights Reserved by MedPath